Supernus Pharmaceuticals Inc
SUPN46.135USD
+1.335+2.98%
交易中 （美东）报价延迟15分钟
2.59B总市值
40.14市盈率 TTM
关于 Supernus Pharmaceuticals Inc 公司
Supernus Pharmaceuticals, Inc. 是一家生物制药公司。该公司专注于开发和商业化用于治疗中枢神经系统 (CNS) 疾病的产品。其多样化的神经科学产品组合包括已获批的治疗癫痫、偏头痛、注意力缺陷多动障碍 (ADHD)、帕金森病 (PD) 中的运动障碍、颈部肌张力障碍、慢性流涎症、接受左旋多巴治疗的 PD 患者的运动障碍以及成人患者药物引起的锥体外系反应的药物。该公司还在开发一系列新型 CNS 产品候选药物，包括用于治疗 PD 中的运动障碍、癫痫、抑郁症和其他 CNS 疾病的新潜在疗法。其商业产品包括 Qelbree（维洛沙嗪）、GOCOVRI（金刚烷胺）、Oxtellar XR（奥卡西平）、Trokendi XR（托吡酯）、APOKYN（盐酸阿扑吗啡注射液）等。 Qelbree（维洛沙嗪）是一种新型非兴奋剂产品，用于治疗 ADHD。
公司简介
公司代码SUPN
公司名称Supernus Pharmaceuticals Inc
上市日期Dec 28, 2010
CEOMr. Jack A. Khattar
员工数量674
证券类型Ordinary Share
年结日Dec 28
公司地址9715 Key West Avenue
城市ROCKVILLE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编20850
电话13018382500
网址https://www.supernus.com
公司代码SUPN
上市日期Dec 28, 2010
CEOMr. Jack A. Khattar
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.12M
+0.92%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
Dr. Jonathan Rubin, M.D.
Dr. Jonathan Rubin, M.D.
Senior Vice President, Chief Medical Officer - Research and Development
Senior Vice President, Chief Medical Officer - Research and Development
9.63K
+8.32%
Mr. Timothy C. (Tim) Dec, CPA
Mr. Timothy C. (Tim) Dec, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
901.00
-92.89%
Mr. Charles W. Newhall, III
Mr. Charles W. Newhall, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bethany L. Sensenig
Ms. Bethany L. Sensenig
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.12M
+0.92%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
其他
16.41M
10.96%
地区USD
名称
营收
占比
United States
149.82M
100.00%
业务
地区
业务USD
名称
营收
占比
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
其他
16.41M
10.96%
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
14.29%
The Vanguard Group, Inc.
11.04%
Armistice Capital LLC
8.58%
Dimensional Fund Advisors, L.P.
5.39%
Macquarie Investment Management
4.93%
其他
55.77%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
14.29%
The Vanguard Group, Inc.
11.04%
Armistice Capital LLC
8.58%
Dimensional Fund Advisors, L.P.
5.39%
Macquarie Investment Management
4.93%
其他
55.77%
股东类型
持股股东
占比
Investment Advisor
55.47%
Investment Advisor/Hedge Fund
29.99%
Hedge Fund
17.53%
Individual Investor
4.23%
Research Firm
2.61%
Pension Fund
1.62%
Venture Capital
1.50%
Bank and Trust
0.70%
Sovereign Wealth Fund
0.10%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
565
63.61M
113.46%
-2.51M
2025Q1
587
64.77M
115.71%
-2.86M
2024Q4
569
65.17M
116.92%
-2.59M
2024Q3
551
65.02M
117.72%
-2.14M
2024Q2
536
63.49M
115.33%
-2.27M
2024Q1
535
61.47M
111.83%
-3.83M
2023Q4
534
61.60M
112.54%
-3.30M
2023Q3
534
60.88M
111.42%
-4.46M
2023Q2
534
61.11M
111.93%
-1.60M
2023Q1
539
59.34M
108.94%
-3.56M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
8.20M
14.65%
-297.23K
-3.50%
Mar 31, 2025
The Vanguard Group, Inc.
6.15M
10.99%
+13.13K
+0.21%
Mar 31, 2025
Armistice Capital LLC
5.20M
9.28%
+360.00K
+7.44%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.90M
5.19%
+25.18K
+0.87%
Mar 31, 2025
Macquarie Investment Management
2.70M
4.82%
+70.76K
+2.69%
Mar 31, 2025
State Street Global Advisors (US)
2.15M
3.83%
-42.85K
-1.96%
Mar 31, 2025
Khattar (Jack A)
2.01M
3.6%
--
--
Apr 22, 2025
Renaissance Technologies LLC
1.59M
2.83%
-13.00K
-0.81%
Mar 31, 2025
Stephens Investment Management Group, LLC
1.74M
3.1%
-13.59K
-0.78%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.33M
2.37%
-183.95K
-12.18%
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
